LIVIVO - Search results -

Search results

Result 1 - 10 of total 28

Search options

Article: Topical therapy for the management of childhood psoriasis: part I.

Cordoro, K M

2008 Volume 13, Issue 3, Page(s) 1–3

Abstract: Psoriasis represents a potentially life-altering disease that can profoundly impact physical, emotional and social functioning, and overall quality of life. The majority of cases are mild and managed adequately with topical medications. A minor subset of ...

Abstract	Psoriasis represents a potentially life-altering disease that can profoundly impact physical, emotional and social functioning, and overall quality of life. The majority of cases are mild and managed adequately with topical medications. A minor subset of children present with severe, rapidly evolving disease that requires systemic therapy. The choice of treatment in children, as in adults, is determined by disease acuity, morphology, distribution, severity and the presence of comorbidities such as psoriatic arthropathy. Practical considerations such as ease of use, patient acceptability, accessibility, risk to benefit ratio, cost and individual perceptions of disease and quality of life are factored into treatment decisions. Part I of this 2-part series will focus on topical agents, their varying degrees of effectiveness, potential side-effects and applications in clinical practice.
MeSH term(s)	Administration, Cutaneous ; Child ; Dermatologic Agents/adverse effects ; Dermatologic Agents/therapeutic use ; Glucocorticoids/adverse effects ; Glucocorticoids/therapeutic use ; Humans ; Keratolytic Agents/adverse effects ; Keratolytic Agents/therapeutic use ; Psoriasis/drug therapy
Chemical Substances	Dermatologic Agents ; Glucocorticoids ; Keratolytic Agents
Language	English
Publishing date	2008-04
Publishing country	Canada
Document type	Journal Article ; Review
ZDB-ID	2065394-3
ISSN	1201-5989
ISSN	1201-5989
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5605: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article: Systemic and light therapies for the management of childhood psoriasis: part II.

Cordoro, K M

Skin therapy letter

2008 Volume 13, Issue 4, Page(s) 1–3

Abstract: The choice of treatment for psoriasis in children, as in adults, is determined by disease acuity, morphology, distribution, severity, and the presence of comorbidities, such as psoriatic arthropathy. Fortunately, most patients present with mild disease ... ...

Abstract	The choice of treatment for psoriasis in children, as in adults, is determined by disease acuity, morphology, distribution, severity, and the presence of comorbidities, such as psoriatic arthropathy. Fortunately, most patients present with mild disease that responds adequately to topical medications. A minor subset of children will present with severe, rapidly evolving disease that requires more aggressive interventions. Advanced medical treatment with systemic and phototherapy is challenging and primarily anecdotal, as these modalities are neither well-studied nor approved for use in children. Part II of this 2-part series features an overview of systemic and light therapies including their varying degrees of effectiveness, potential side-effects and applications in clinical practice.
MeSH term(s)	Biological Products/therapeutic use ; Child ; Cyclosporine/therapeutic use ; Dermatologic Agents/therapeutic use ; Humans ; Methotrexate/therapeutic use ; Phototherapy ; Psoriasis/therapy ; Retinoids/therapeutic use
Chemical Substances	Biological Products ; Dermatologic Agents ; Retinoids ; Cyclosporine (83HN0GTJ6D) ; Methotrexate (YL5FZ2Y5U1)
Language	English
Publishing date	2008-05
Publishing country	Canada
Document type	Journal Article
ZDB-ID	2065394-3
ISSN	1201-5989
ISSN	1201-5989
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5605: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: The evolving role of biologics in the treatment of pediatric psoriasis.

Luu, M / Cordoro, K M

Skin therapy letter

2013 Volume 18, Issue 2, Page(s) 1–4

Abstract: The exact role of biologics in the treatment of pediatric psoriasis remains undefined but is evolving. Biologics are an attractive option for use in children in part because they offer more convenient dosing regimens and less frequent laboratory ... ...

Abstract	The exact role of biologics in the treatment of pediatric psoriasis remains undefined but is evolving. Biologics are an attractive option for use in children in part because they offer more convenient dosing regimens and less frequent laboratory monitoring than traditional systemic agents. Further, because their action is targeted, they theoretically lack many of the potential end-organ toxicities of traditional agents. However, compared to adult psoriasis populations, there is a relative lack of long-term safety data specific to the pediatric psoriasis population. Thus, the clear advantages of using biologic agents must be balanced with a measure of caution. This article will provide a summary of the cumulative pediatric safety and efficacy data for the anti-tumor necrosis factor-alpha (TNF-α) agents and interleukin (IL)-12 and IL-23 (IL12/23) pathway inhibitor and suggestions for a rational clinical approach to their use in children with psoriasis.
MeSH term(s)	Adalimumab ; Adolescent ; Antibodies, Monoclonal/adverse effects ; Antibodies, Monoclonal/therapeutic use ; Antibodies, Monoclonal, Humanized/adverse effects ; Antibodies, Monoclonal, Humanized/therapeutic use ; Child ; Child, Preschool ; Dermatologic Agents/adverse effects ; Dermatologic Agents/therapeutic use ; Dose-Response Relationship, Drug ; Etanercept ; Humans ; Immunoglobulin G/adverse effects ; Immunoglobulin G/therapeutic use ; Infant ; Infliximab ; Psoriasis/drug therapy ; Receptors, Tumor Necrosis Factor/therapeutic use ; Severity of Illness Index ; Tumor Necrosis Factor-alpha/antagonists & inhibitors ; Ustekinumab
Chemical Substances	Antibodies, Monoclonal ; Antibodies, Monoclonal, Humanized ; Dermatologic Agents ; Immunoglobulin G ; Receptors, Tumor Necrosis Factor ; Tumor Necrosis Factor-alpha ; Infliximab (B72HH48FLU) ; Ustekinumab (FU77B4U5Z0) ; Adalimumab (FYS6T7F842) ; Etanercept (OP401G7OJC)
Language	English
Publishing date	2013-02
Publishing country	Canada
Document type	Journal Article
ZDB-ID	2065394-3
ISSN	1201-5989
ISSN	1201-5989
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5605: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: TNF-alpha inhibitors in dermatology.

Cordoro, K M / Feldman, S R

Skin therapy letter

2007 Volume 12, Issue 7, Page(s) 4–6

Abstract: To date, the US FDA has approved three tumor necrosis factor (TNF)-a inhibitors for use in dermatology. Etanercept (Enbrel, Amgen-Wyeth), a fully human fusion protein of TNF receptor II bound to the Fc component of human IgG1, is approved for use in ... ...

Abstract	To date, the US FDA has approved three tumor necrosis factor (TNF)-a inhibitors for use in dermatology. Etanercept (Enbrel, Amgen-Wyeth), a fully human fusion protein of TNF receptor II bound to the Fc component of human IgG1, is approved for use in psoriasis (2004) and psoriatic arthritis (2002). Infliximab (Remicade, Centocor) is a chimeric monoclonal antibody that is approved for use in psoriasis (2006) and psoriatic arthritis (2005), and adalimumab (Humira, Abbott Laboratories), a fully human monoclonal antibody, is approved for use in psoriatic arthritis (2005). While data regarding the efficacy and safety of these therapies is abundant, it proves nearly impossible to objectively compare and contrast agents as there are no head-to-head trials. Clinical experience and post-marketing reporting has allowed dermatologists to identify the relative strengths and limitations of each agent. The well-founded enthusiasm for these agents, because of their excellent initial efficacy and safety profile, is reasonably tempered by concerns about declining efficacy over time, the risk of infection, lymphoma and demyelinating disorders, and cost. The distinct and targeted mechanism of action of the TNF inhibitors allows dermatologists to customize therapy to match the individual needs and characteristics of patients who are candidates for systemic or phototherapy.
MeSH term(s)	Adalimumab ; Anti-Inflammatory Agents/therapeutic use ; Antibodies, Monoclonal/therapeutic use ; Antibodies, Monoclonal, Humanized ; Arthritis, Psoriatic/drug therapy ; Etanercept ; Humans ; Immunoglobulin G/therapeutic use ; Infliximab ; Psoriasis/drug therapy ; Receptors, Tumor Necrosis Factor/therapeutic use ; Tumor Necrosis Factor-alpha/antagonists & inhibitors
Chemical Substances	Anti-Inflammatory Agents ; Antibodies, Monoclonal ; Antibodies, Monoclonal, Humanized ; Immunoglobulin G ; Receptors, Tumor Necrosis Factor ; Tumor Necrosis Factor-alpha ; Infliximab (B72HH48FLU) ; Adalimumab (FYS6T7F842) ; Etanercept (OP401G7OJC)
Language	English
Publishing date	2007-09
Publishing country	Canada
Document type	Journal Article ; Review
ZDB-ID	2065394-3
ISSN	1201-5989
ISSN	1201-5989
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5605: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Concurrent Subcutaneous Panniculitis-like T-Cell Lymphoma and B-Cell Acute Lymphoblastic Leukemia in 2 Pediatric Patients.

Smith, Geoffrey A / Levinson, Anya L / Galvin, Robert T / Lalor, Leah E / McCalmont, Timothy / Wang, Linlin / Geis, Michael C / Odegaard, Karah / Hupp, Meghan / Maguiness, Sheilagh / Turcotte, Lucie M / Cordoro, Kelly M / Hermiston, Michelle L

Journal of pediatric hematology/oncology

2020 Volume 43, Issue 6, Page(s) e791–e794

Abstract: Subcutaneous panniculitis-like T-cell lymphoma is a cutaneous lymphoma characterized by CD8+ T-cell infiltrate in the subcutis that is rare in children. Acute lymphoblastic lymphoma is the most common pediatric malignancy and often presents with fevers ... ...

Abstract	Subcutaneous panniculitis-like T-cell lymphoma is a cutaneous lymphoma characterized by CD8+ T-cell infiltrate in the subcutis that is rare in children. Acute lymphoblastic lymphoma is the most common pediatric malignancy and often presents with fevers and pancytopenia. Herein, we report 2 pediatric patients presenting with subcutaneous panniculitis-like T-cell lymphoma and B-cell acute lymphoblastic lymphoma, distinct hematologic malignancies arising from different lymphoid lineages, with no identifiable germline cancer predisposition.
MeSH term(s)	B-Lymphocytes/pathology ; CD8-Positive T-Lymphocytes/pathology ; Child, Preschool ; Female ; Humans ; Lymphoma, T-Cell/complications ; Lymphoma, T-Cell/diagnosis ; Lymphoma, T-Cell/pathology ; Male ; Panniculitis/complications ; Panniculitis/diagnosis ; Panniculitis/pathology ; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/complications ; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/diagnosis ; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/pathology
Language	English
Publishing date	2020-07-10
Publishing country	United States
Document type	Case Reports ; Journal Article
ZDB-ID	1231152-2
ISSN	1536-3678 ; 1077-4114 ; 0192-8562
ISSN (online)	1536-3678
ISSN	1077-4114 ; 0192-8562
DOI	10.1097/MPH.0000000000001921
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1537: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Dermatology COVID-19 Registries: Updates and Future Directions.

Dermatologic clinics

2021 Volume 39, Issue 4, Page(s) 575–585

Abstract: During the COVID-19 pandemic, rapid, real-world evidence is essential for the development of knowledge and subsequent public health response. In dermatology, provider-facing and patient-facing registries focused on COVID-19 have been important sources of ...

Abstract	During the COVID-19 pandemic, rapid, real-world evidence is essential for the development of knowledge and subsequent public health response. In dermatology, provider-facing and patient-facing registries focused on COVID-19 have been important sources of research and new information aimed at guiding optimal patient care. The 7 dermatology registries included in this update now include more than 8000 case reports sourced from physicians and patients from countries all over the world.
MeSH term(s)	COVID-19/epidemiology ; Disease Susceptibility ; Humans ; Prevalence ; Registries/statistics & numerical data ; Risk Factors ; Skin Diseases/epidemiology
Language	English
Publishing date	2021-05-31
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	82798-8
ISSN	1558-0520 ; 0733-8635
ISSN (online)	1558-0520
ISSN	0733-8635
DOI	10.1016/j.det.2021.05.013
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Se 851: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Clinical report: A patient with a late diagnosis of cerebrotendinous xanthomatosis and a response to treatment.

Alhariri, Ahmad / Hamilton, Katherine / Oza, Vikash / Cordoro, Kelly / Sobreira, Nara L / Malloy, Mary / Slavotinek, Anne

American journal of medical genetics. Part A

2017 Volume 173, Issue 8, Page(s) 2275–2279

Abstract: Cerebrotendinous xanthomatosis (CTX) is a rare, autosomal recessive, inborn error of bile acid metabolism characterized by diarrhea in infancy, juvenile cataracts in childhood, tendon xanthomas developing in the second to third decades of life, and ... ...

Abstract	Cerebrotendinous xanthomatosis (CTX) is a rare, autosomal recessive, inborn error of bile acid metabolism characterized by diarrhea in infancy, juvenile cataracts in childhood, tendon xanthomas developing in the second to third decades of life, and progressive neurologic dysfunction in adulthood. The condition is caused by mutations in the CYP27A1 gene that result in decreased production of chenodeoxycholic acid (CDCA) and elevated levels of cholestanol and bile alcohols. We present a 36-year-old male of Han ethnicity who developed xanthomas of his Achilles tendons and suffered neurocognitive declines and gait deterioration in his second decade. The diagnosis of CTX was confirmed by marked elevation of the serum cholestanol level. Sequencing of CYP27A1 showed a paternally inherited splice mutation, c.446 + 1G>T, and a maternally inherited nonsense mutation, c.808C>T, predicting p.(Arg270*). Despite the advanced disease in this patient, treatment with CDCA reduced the xanthoma size and improved his cognition and strength, and the patient made significant gains in his ambulation and coordination. We report this case to illustrate the potential benefits of therapy in patients with CTX who have advanced disease at the time of diagnosis.
MeSH term(s)	Achilles Tendon/drug effects ; Achilles Tendon/physiopathology ; Adult ; Bile Acids and Salts/genetics ; Bile Acids and Salts/metabolism ; Chenodeoxycholic Acid/administration & dosage ; Chenodeoxycholic Acid/metabolism ; Cholestanetriol 26-Monooxygenase/genetics ; Cholestanol/blood ; Codon, Nonsense ; Humans ; Male ; Xanthomatosis, Cerebrotendinous/blood ; Xanthomatosis, Cerebrotendinous/drug therapy ; Xanthomatosis, Cerebrotendinous/genetics ; Xanthomatosis, Cerebrotendinous/physiopathology
Chemical Substances	Bile Acids and Salts ; Codon, Nonsense ; Chenodeoxycholic Acid (0GEI24LG0J) ; Cholestanol (8M308U816E) ; CYP27A1 protein, human (EC 1.14.15.15) ; Cholestanetriol 26-Monooxygenase (EC 1.14.15.15)
Language	English
Publishing date	2017-06-07
Publishing country	United States
Document type	Case Reports ; Journal Article
ZDB-ID	1493479-6
ISSN	1552-4833 ; 1552-4825
ISSN (online)	1552-4833
ISSN	1552-4825
DOI	10.1002/ajmg.a.38314
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: A Comparison of Psoriasis Severity in Pediatric Patients Treated With Methotrexate vs Biologic Agents.

JAMA dermatology

2020 Volume 156, Issue 4, Page(s) 384–392

Abstract: Importance: Few studies have compared the use of methotrexate and biologics, the most commonly used systemic medications for treatment of moderate to severe psoriasis in children.: Objective: To assess the real-world, 6-month reduction in psoriasis ... ...

Abstract	Importance: Few studies have compared the use of methotrexate and biologics, the most commonly used systemic medications for treatment of moderate to severe psoriasis in children. Objective: To assess the real-world, 6-month reduction in psoriasis severity and long-term drug survival (rate and duration of adherence to a specific drug) of methotrexate vs biologics in plaque psoriasis in children. Design, setting, and participants: A retrospective medical records review was conducted at 20 European and North American centers. Treatment response was based on site-reported Psoriasis Area and Severity Index (PASI) and/or Physician Global Assessment (PGA) scores at baseline and within the first 6 months of treatment. Participants included all 234 consecutively seen children with moderate to severe psoriasis who received at least 3 months of methotrexate or biologics from December 1, 1990, to September 16, 2014, with sufficient data for analysis. Data analysis was performed from December 14, 2015, to September 1, 2016. Main outcomes and measures: PASI, with a range from 0 to 72 (highest score indicating severe psoriasis), and/or PGA, with a scale of 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), and 5 (very severe). Results: Of 234 pediatric patients (103 boys [44.0%]; 131 girls [56.0%]) treated with methotrexate and/or biologics, 163 patients (69.7%) exclusively received methotrexate, 47 patients (20.1%) exclusively received biologics, and 24 children (10.2%) received methotrexate and biologics sequentially. Of the latter cohort, 23 children were treated initially with methotrexate. Mean (SD) age at initiation was 11.6 (3.7) years for methotrexate and 13.3 (2.9) years for biologics (73.2% for etanercept) (P = .002). Among patients evaluated by a scoring method at 6-month follow-up, 75% or greater improvement in PASI (PASI75) was achieved in 12 of 30 patients (40.0%) receiving methotrexate and 20 of 28 patients (71.4%) receiving biologics, and PGA was clear/almost clear (PGA 0/1) in 41 of 115 patients (35.6%) receiving methotrexate and 18 of 37 patients (48.6%) receiving biologics. Achieving PASI75 and/or PGA 0/1 between baseline and 6 months was more likely with biologics than methotrexate (PASI75: odds ratio [OR], 4.56; 95% CI, 2.02-10.27; P < .001; and PGA 0/1: OR, 2.00; 95% CI, 0.98-4.00; P = .06). Decreased mean PASI and PGA scores were associated with biologics more than with methotrexate (PASI effect, -3.13; 95% CI, -4.33 to -1.94; P < .001; and PGA effect, -0.31; 95% CI, -0.56 to -0.06; P = .02). After 1, 3, and 5 years of use, overall drug survival rates for methotrexate were 77.5%, 50.3%, and 35.9%, and for biologics, the rates were 83.4%, 64.3%, and 57.1%, respectively. Biologics were associated with a better confounder-corrected drug survival than methotrexate (hazard ratio [HR], 2.23; 95% CI, 1.21-4.10; P = .01). Discontinuation owing to lack of response was comparable (HR, 1.64; 95% CI, 0.80-3.36; P = .18). Conclusions and relevance: Methotrexate and biologics appear to be associated with improvement in pediatric psoriasis, although biologics seem to be associated with greater reduction in psoriasis severity scores and higher drug survival rates than methotrexate in the real-world setting. Additional studies directly comparing these medications should be performed for confirmation.
MeSH term(s)	Adolescent ; Biological Factors/administration & dosage ; Child ; Cohort Studies ; Etanercept/administration & dosage ; Female ; Humans ; Male ; Methotrexate/administration & dosage ; Psoriasis/drug therapy ; Psoriasis/physiopathology ; Retrospective Studies ; Severity of Illness Index ; Survival Rate
Chemical Substances	Biological Factors ; Etanercept (OP401G7OJC) ; Methotrexate (YL5FZ2Y5U1)
Language	English
Publishing date	2020-02-06
Publishing country	United States
Document type	Comparative Study ; Journal Article ; Multicenter Study ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
ZDB-ID	2701761-8
ISSN	2168-6084 ; 2168-6068
ISSN (online)	2168-6084
ISSN	2168-6068
DOI	10.1001/jamadermatol.2019.4835
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ui VI Zs.32: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: A retrospective multicenter study of fatal pediatric melanoma.

Hawryluk, Elena B / Moustafa, Danna / Bartenstein, Diana / Brahmbhatt, Meera / Cordoro, Kelly / Gardner, Laura / Gauthier, Abigail / Grossman, Douglas / Gupta, Deepti / Hunt, Raegan D / Jen, Melinda / Kao, Pei-Chi / Kruse, Lacey L / Lawley, Leslie P / London, Wendy B / Mansour, Danny / O'Haver, Judith A / Phung, Thuy / Pope, Elena /

Price, Harper N / Rogers, Tova / Shah, Sonal D / Wolner, Zachary / Huang, Jennifer / Marghoob, Ashfaq A

Journal of the American Academy of Dermatology

2020 Volume 83, Issue 5, Page(s) 1274–1281

Abstract: Background: Pediatric melanoma is rare and diagnostically challenging.: Objective: To characterize clinical and histopathologic features of fatal pediatric melanomas.: Methods: Multicenter retrospective study of fatal melanoma cases in patients ... ...

Abstract	Background: Pediatric melanoma is rare and diagnostically challenging. Objective: To characterize clinical and histopathologic features of fatal pediatric melanomas. Methods: Multicenter retrospective study of fatal melanoma cases in patients younger than 20 years diagnosed between 1994 and 2017. Results: Of 38 cases of fatal pediatric melanoma identified, 57% presented in white patients and 19% in Hispanic patients. The average age at diagnosis was 12.7 years (range, 0.0-19.9 y), and the average age at death was 15.6 years (range, 1.2-26.2 y). Among cases with known identifiable subtypes, 50% were nodular (8/16), 31% were superficial spreading (5/16), and 19% were spitzoid melanoma (3/16). One fourth (10/38) of melanomas arose in association with congenital melanocytic nevi. Limitations: Retrospective nature, cohort size, and potential referral bias. Conclusions: Pediatric melanoma can be fatal in diverse clinical presentations, including a striking prevalence of Hispanic patients compared to adult disease, and with a range of clinical subtypes, although no fatal cases of spitzoid melanoma were diagnosed during childhood.
MeSH term(s)	Adolescent ; Adult ; Child ; Child, Preschool ; Female ; Humans ; Infant ; Male ; Melanoma/diagnosis ; Melanoma/mortality ; Retrospective Studies ; Skin Neoplasms/diagnosis ; Skin Neoplasms/mortality ; Young Adult
Language	English
Publishing date	2020-07-02
Publishing country	United States
Document type	Journal Article ; Multicenter Study
ZDB-ID	603641-7
ISSN	1097-6787 ; 0190-9622
ISSN (online)	1097-6787
ISSN	0190-9622
DOI	10.1016/j.jaad.2020.06.1010
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1540: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Skin-infiltrating, interleukin-22-producing T cells differentiate pediatric psoriasis from adult psoriasis.

Cordoro, Kelly M / Hitraya-Low, Maria / Taravati, Keyon / Sandoval, Priscila Munoz / Kim, Esther / Sugarman, Jeffrey / Pauli, Mariela L / Liao, Wilson / Rosenblum, Michael D

Journal of the American Academy of Dermatology

2017 Volume 77, Issue 3, Page(s) 417–424

Abstract: Background: Evidence from adult psoriasis studies implicates an imbalance between regulatory and effector T cells, particularly T: Objective: We sought to functionally characterize the inflammatory cell profiles of psoriatic plaques from pediatric ... ...

Abstract	Background: Evidence from adult psoriasis studies implicates an imbalance between regulatory and effector T cells, particularly T Objective: We sought to functionally characterize the inflammatory cell profiles of psoriatic plaques from pediatric patients and compare them with healthy, age-matched controls and adult psoriasis patients. Methods: Skin samples from pediatric psoriasis patients and healthy controls were analyzed by multiparameter flow cytometry to determine the dominant immune cell subsets present and cytokines produced. Results: Lesional tissue from pediatric psoriasis patients had significantly increased interleukin (IL) 22 derived from CD4 Limitations: This is a pilot study, thus the sample size is small. Conclusion: Significant differences in IL-17 and IL-22 expression were observed in the pediatric psoriasis patients compared with pediatric healthy controls and adult psoriasis patients. IL-22 might be relevant in the pathogenesis of pediatric psoriasis and represents a potential treatment target unique to pediatric psoriasis.
MeSH term(s)	Adolescent ; Adult ; Age Factors ; Child ; Child, Preschool ; Female ; Humans ; Infant ; Interleukin-17/biosynthesis ; Interleukins/biosynthesis ; Male ; Pilot Projects ; Psoriasis/immunology ; Psoriasis/pathology ; T-Lymphocytes/immunology ; T-Lymphocytes/metabolism ; Interleukin-22
Chemical Substances	Interleukin-17 ; Interleukins
Language	English
Publishing date	2017-06-16
Publishing country	United States
Document type	Comparative Study ; Journal Article
ZDB-ID	603641-7
ISSN	1097-6787 ; 0190-9622
ISSN (online)	1097-6787
ISSN	0190-9622
DOI	10.1016/j.jaad.2017.05.017
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1540: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito